{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:49:07Z","timestamp":1792658947753,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001626","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001626","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ijantimicag.2019.04.012","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T18:30:37Z","timestamp":1556303437000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007\u20132016"],"prefix":"10.1016","volume":"54","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5826-2869","authenticated-orcid":false,"given":"Philippe R.S.","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Laing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0001","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/00325481.2017.1246055","article-title":"An update on the management of urinary tract infections in the era of antimicrobial resistance","volume":"129","author":"Bader","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0002","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0196-4399(02)80035-6","article-title":"Epidemiology of urinary tract infections","volume":"24","author":"Nicolle","year":"2001","journal-title":"Clin Microbiol Newsl"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/520138","article-title":"Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis","volume":"29","author":"Echols","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0005","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of uncomplicated acute cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0006","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010\u20132014","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0007","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/cid\/ciw396","article-title":"Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens","volume":"63","author":"Walker","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0008","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1302186","article-title":"Voided midstream urine culture and acute cystitis in premenopausal women","volume":"369","author":"Hooton","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clinmicnews.2018.01.003","article-title":"Impact of reflex algorithms on urine culture utilization","volume":"40","author":"Yarborough","year":"2018","journal-title":"Clin Microbiol Newsl"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/427507","article-title":"Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults","volume":"40","author":"Nicolle","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0011","series-title":"Choosing Wisely Canada \u2013 Medical Microbiology","year":"2017"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0012","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0013","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0014","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/jac\/dky214","article-title":"Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disk diffusion","volume":"73","author":"van den Bijllaardt","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.diagmicrobio.2018.07.014","article-title":"Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methods","volume":"93","author":"Camarlinghi","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0016","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/AAC.06060-11","article-title":"In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010","volume":"56","author":"Sanchez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0017","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1093\/jac\/dku282","article-title":"Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients","volume":"69","author":"Sanchez","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0018","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/AAC.02897-15","article-title":"Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012","volume":"60","author":"Sanchez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0019","series-title":"Biggest threats and data","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3810\/pgm.2008.09.suppl52.285","article-title":"Stratified analysis of multidrug-resistant Escherichia coli in US health care institutions","volume":"120","author":"Sahm","year":"2008","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s15010-016-0910-2","article-title":"Incidence of urinary tract infections and antibiotic resistance in the outpatient setting: a cross-sectional study","volume":"45","author":"Rossignol","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0022","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/AAC.02399-13","article-title":"In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study","volume":"58","author":"Karlowsky","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0023","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1128\/AAC.00066-11","article-title":"Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study","volume":"55","author":"Karlowsky","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0024","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2006.02.009","article-title":"Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)","volume":"27","author":"Zhanel","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmi.2015.08.019","article-title":"Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries","volume":"22","author":"Kresken","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0026","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.diagmicrobio.2010.10.027","article-title":"Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada\u2014results of the CANWARD 2007\u20132009 study","volume":"69","author":"Lagac\u00e9-Wiens","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.04.012_bib0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkt022","article-title":"Antimicrobial susceptibility of 22,746 pathogens from Canadian hospitals; results of the CANWARD 2007\u20132011 study","volume":"68","author":"Zhanel","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0028","series-title":"Abbreviated identification of bacteria and yeast; approved guideline","year":"2008"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0029","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.diagmicrobio.2010.10.029","article-title":"Prevalence and characterization of extended-spectrum \u03b2-lactamase- and AmpC \u03b2-lactamase-producing Escherichia coli: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Simner","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0031","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0032","series-title":"IDWeek 2017","article-title":"Prevalence of extended-spectrum \u03b2-lactamase producing and quinolone non-susceptible Enterobacteriaceae in inpatient and outpatient settings in the USA from 2011\u20132017","author":"Puttagunta","year":"2017"},{"key":"10.1016\/j.ijantimicag.2019.04.012_bib0033","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/j.1469-0691.2011.03519.x","article-title":"Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting","volume":"17","author":"Kronenberg","year":"2011","journal-title":"Clin Microbiol Infect"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T22:37:19Z","timestamp":1565131039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0924857919301062"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.04.012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007\u20132016","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}